Nolavetbart Biosimilar - Research Grade

Human

IL31RA

>1mg/ml

IgG2 - kappa

CHO Cells

Nemolizumab Biosimilar - Research Grade (ICH5123)

https://www.imgt.org/mAb-DB/

ICH3002

Q8NI17

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of Nolavetbart, supplied strictly for research use only (RUO). It is not the clinical or veterinary drug and is not intended for human or animal treatment. The molecule is a recombinant IgG2-kappa antibody built around the interleukin-31 receptor subunit alpha (IL31RA) target, produced to reproduce the target-binding behaviour of the originator without any therapeutic claim. It is offered as an in-vitro reference standard and research reagent, useful as a positive binding control, as a benchmarking tool when characterising anti-IL31RA reagents, for epitope-competition and receptor-blockade assays, and as an input for antibody-engineering and assay-development workflows. Material is manufactured at research grade with low endotoxin (typically less than 1 EU/mg, with an ultra-low option below 0.5 EU/mg) and is available in bulk milligram-to-gram quantities to support screening campaigns and preclinical, non-clinical laboratory studies. It carries no fluorophore or enzyme conjugate, leaving it flexible for downstream labelling or format conversion by the end user. IL31RA (interleukin-31 receptor subunit alpha; UniProt Q8NI17) is a type I cytokine receptor chain and the ligand-specific component of the interleukin-31 receptor. It does not signal alone: IL-31 first engages IL31RA, and the complex then recruits the oncostatin M receptor beta chain (OSMR) to assemble the functional heterodimeric receptor. Receptor assembly activates JAK1/JAK2 and downstream STAT3 (with lesser STAT1 and STAT5 input), as well as PI3K/AKT and MAPK branches. IL31RA is expressed on sensory dorsal root ganglion neurons, keratinocytes, monocytes/macrophages, and epithelial cells, positioning it at the interface of the immune system, epithelium, and the peripheral nervous system. This axis is a principal driver of pruritus and is implicated in type 2 inflammatory skin disease, making IL31RA a well-studied target for itch and inflammation research.

IL-31 receptor A, IL-31 receptor subunit alpha, IL-31R subunit alpha, IL-31R-alpha, Cytokine receptor-like 3, Gp130-like monocyte receptor, GLM-R, hGLM-R, Gp130-like receptor, GPL, ZcytoR17, Interleukin-31 receptor subunit alpha, CRL3

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Nolavetbart biosimilar available in bulk or gram quantities?

A: Yes — the Nolavetbart biosimilar is manufactured in scalable milligram to gram quantities to support high-throughput and heavy-usage laboratories.

Q: Is research-grade Nolavetbart suitable for in vivo studies?

A: Yes, it is supplied as a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Nolavetbart biosimilar target?

A: It is an unconjugated, non-therapeutic biosimilar monoclonal antibody analogous to Nolavetbart that binds IL31RA; for research use only (RUO).